Janssen Forms Global Public Health Group To Deliver Its Medicines To Developing World
This article was originally published in PharmAsia News
With the formation of the GPH group, Janssen joins GSK and Sanofi in putting corporate focus on developing and delivering affordable medicines for developing countries. But where GSK seeks to improve outcomes and turn a profit, for now Janssen’s first priority is human health.
You may also be interested in...
Initiative to build health care infrastructure and create a sales channel for GSK medicines is starting to yield tangible results.
The first drug approved for multi-drug resistant tuberculosis, Sirturo obtained accelerated approval based on data from two Phase II studies, but has a troubling safety database, including 10 deaths in the treatment arm of its Phase II program.
Singulair’s Psychiatric AE Risks Still A Problem, But US FDA Has Limited Mitigation Options Remaining
Stakeholders suggested a ‘Dear Healthcare Provider’ letter or speaking about the risks to professional societies to emphasize the psychiatric adverse events that prompted a boxed warning for the now-generic asthma drug montelukast. The NY Attorney General is adding more pressure.